新福菌素注射剂联合奈达铂注射剂治疗局部晚期鼻咽癌的临床研究

发布时间：2019-04-08 13:37

【摘要】：目的探讨联合新福菌素及奈达铂化疗在局部晚期鼻咽癌治疗中的应用价值,为临床更为有效的治疗局部晚期鼻咽癌提供参考。方法将80例局部晚期鼻咽癌患者随机分为对照组40例和试验组40例。2组患者均接受放疗治疗,放疗治疗方案应用调强适形放射治疗方案。对照组给予30 mg·m~(-2)奈达铂,静脉滴注,每周1次;试验组在对照组的基础上给予新福菌素注射剂0.4 mg+5%葡萄糖注射液500 m L,静脉滴注,伴行静脉输液4~5 h,每2 d用药1次。2组均治疗6周。比较2组患者的鼻咽部原发灶和颈部淋巴结转移灶的临床疗效以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为67.50%(27例/40例)和45.00%(18例/40例),差异有统计学意义(P0.05)。治疗后,咽部原发病灶面积均下降,试验组和对照组分别为(19.11±2.07),(23.6±5.51)mm;颈部淋巴结转移分别为(5.49±3.92),(9.24±3.83)mm,差异有统计学意义(P0.05)。试验组和对照组的药物不良反应有骨髓抑制、胃肠道反应、腔黏膜反应、口干反应、皮肤反应。试验组和对照组的药物不良反应发生率分别为82.50%(33例/40例)和72.50%(29例/40例),差异无统计学意义(P0.05)。结论新福菌素联合奈达铂治疗局部晚期鼻咽癌方案临床疗效好,安全性高。
[Abstract]:Objective to explore the clinical value of neomycin and nedabine chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma (NPC), and to provide reference for clinical treatment of locally advanced NPC. Methods 80 patients with locally advanced nasopharyngeal carcinoma (NPC) were randomly divided into control group (n = 40) and test group (n = 40). In the control group, 30 mg 路m ~ (- 2) nedabine was given intravenously once a week. The experimental group was treated with 0.4 mg 5% glucose injection of 0.4 mg 5% glucose 500 mL on the basis of the control group, infused intravenously for 4 hours for 5 hours, once every 2 days. The two groups were treated for 6 weeks. The clinical efficacy and adverse drug reactions of primary nasopharynx focus and cervical lymph node metastasis were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 67.50% (27 / 40) and 45.00% (18 / 40), respectively, the difference was statistically significant (P0.05). After treatment, the primary focus area of pharynx decreased, which was (19.11 卤2.07), () 23.6 卤5.51 mm; in test group and control group, respectively. The cervical lymph node metastasis was (5.49 卤3.92), () 9.24 卤3.83 mm, (P0.05). The adverse drug reactions were myelosuppression, gastrointestinal reaction, cavity mucosal reaction, dry mouth reaction and skin reaction. The incidence of adverse drug reactions in test group and control group were 82.50% (33 / 40) and 72.50% (29 / 40), respectively. There was no significant difference between the two groups (P0.05). Conclusion Neoformectin combined with nedaplatin is effective and safe in the treatment of locally advanced nasopharyngeal carcinoma.
【作者单位】：苏州大学附属第二医院耳鼻喉科;镇江第一人民医院耳鼻喉科;
【基金】：江苏省六大人才高峰基金资助项目(2011021) 苏州市科技计划基金资助项目(SYS201233)
【分类号】：R739.63

【相似文献】